PHIO

Phio Pharmaceuticals Corp. (PHIO) - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company developing immuno-oncology therapeutics using its proprietary INTASYL® small interfering RNA gene silencing technology. The Company operates as a single segment and is currently focused on advancing its lead product candidate, PH-762, in a Phase 1b clinical trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

Effective July 5, 2024, the Company completed a 1-for-9 reverse stock split. As of November 14, 2024, there were 1,055,219 shares of common stock outstanding.

Key Financial Metrics

Note: The Company has no product revenue. All figures are in thousands except per share data.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by 43% in Q3 2024 compared to Q3 2023 ($1.59M vs. $2.78M) and by 36% for the nine-month period. This reduction is primarily attributed to a cost rationalization program implemented in 2023, which included a 36% reduction in headcount and the expiration of the corporate headquarters lease in March 2024.
• Collaboration Termination: In May 2024, the Company terminated its Clinical Co-Development Agreement with AgonOx, Inc. This eliminated future reimbursement obligations (up to $4 million) and potential milestone/royalty income. Remaining accrued obligations to AgonOx as of September 30, 2024, were $35,000.
• Financing Activity: In July 2024, the Company completed a financing transaction involving the exercise of existing warrants at a reduced price ($5.45/share) and the issuance of new warrants. Net proceeds were approximately $2.65 million. This contrasts with the prior year, which saw multiple registered direct offerings.
• Reverse Stock Split: A 1-for-9 reverse stock split was executed in July 2024, adjusting all share and per-share data retrospectively.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: The Company has reported recurring losses since inception and has not generated product revenue. Management states that current cash resources ($5.39M) may not be sufficient to fund operations for at least the next 12 months. This raises substantial doubt about the Company's ability to continue as a going concern without additional financing.
• Capital Plan: Management expects current cash to fund operations into Q2 2025. Future funding will depend on equity offerings, debt, or strategic opportunities, which are not guaranteed.
• Nasdaq Compliance Risk: The Company must maintain stockholders' equity of at least $2.5 million to remain listed on the Nasdaq Capital Market. As of September 30, 2024, equity was $4.95 million. Continued operating losses could jeopardize this compliance.
• Clinical Progress: The Phase 1b trial for PH-762 is ongoing. Five patients have enrolled in Cohorts 1 and 2 with no dose-limiting toxicities reported. Enrollment is expected to complete in Q3 2025.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "Q2 2025" funding projection given the high volatility of clinical trial costs and the lack of revenue.
• Nasdaq Listing Status: Monitor future quarterly reports to ensure Stockholders' Equity remains above the $2.5 million threshold required by Nasdaq Listing Rule 5550(b)(1).
• Financing Terms: Review the terms of the July 2024 warrant inducement and the dilution impact of the 1,294,886 outstanding warrants (weighted average exercise price $21.62).
• AgonOx Wind-down: Confirm that the $35,000 remaining liability to AgonOx is fully settled and that no contingent liabilities remain from the terminated collaboration.
• Headcount Stability: Assess whether the 36% headcount reduction achieved in 2023 is sustainable for the duration of the Phase 1b trial.